Caricamento quotazioni...
Previsioni
| Acquista |
18 |
| Mantieni |
4 |
| Vendi |
3 |
Notizie Vai al feed delle notizie
Novo Nordisk taps Anthropic AI Claude to speed up drug development
Novo Nordisk has entered a partnership with Anthropic and will test the AI model Claude, including Claude Science, to address scientific questions in the drug discovery process and advance AI-driven software development. The collaboration aims to develop targeted solutions and workflows to accelerate drug research; AI will be used under human supervision. Novo shares in Copenhagen fell about 0.2% at one point, trading at 275.35 DKK. » Altro su finanzen.net
Novo Nordisk faces mid-term rebound but long-term caution after revenue downgrades
Novo Nordisk is expected to see a short-term stock price recovery following a significant decline and two downward revenue revisions, but analysts urge caution due to reduced growth expectations and lower free cash flow forecasts. The company's valuation appears less attractive despite a lower P/E ratio, as its market cap remains high relative to earnings. Technical analysis suggests a temporary bounce, but further selling pressure may resume in the longer term. » Altro su investing.com
Novo Nordisk downgraded to 'neutral' by UBS due to uncertain outlook
UBS has downgraded Novo Nordisk from 'buy' to 'neutral' and significantly lowered its price target. The bank sees major challenges ahead for the Danish pharmaceutical company, particularly regarding its weight loss drugs Wegovy and Ozempic. The outlook for the company's cash flow is also considered uncertain. » Altro su finanzen.net
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | 2023 | |
|---|---|---|
| Ricavi | 232,26 Mld | 31,26% |
| Utile lordo | 196,5 Mld | 32,32% |
| Utile netto | 83,68 Mld | 50,71% |
| EBITDA | 114,63 Mld | 50,01% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 406,69 Mld € |
Numero di azioni | 4,45 Mld |
Massimo/minimo a 52 settimane | 185,12 € - 51,65 € |
| Dividendi | No |
Beta | 0,24 |
Rapporto P/E | 10,73 |
Rapporto PEG | 2,14 |
Rapporto P/B | 5,63 |
Rapporto P/S | 3,79 |
Profilo aziendale
Novo Nordisk A/S ist ein Gesundheitsunternehmen, das sich mit der Erforschung, Entwicklung, Herstellung und Vermarktung von pharmazeutischen Produkten befasst. Das Unternehmen ist auch in der Entdeckung, Entwicklung, Herstellung und Vermarktung von pharmazeutischen Produkten tätig. Das Unternehmen ist in zwei Geschäftsbereichen tätig: Diabetes- und Adipositasbehandlung und Biopharmazeutika. Das Segment Diabetes und Adipositas umfasst Insulin, GLP-1, andere proteinbezogene Produkte wie Glucagon, proteinbezogene Verabreichungssysteme und Nadeln sowie orale Antidiabetika. Das Biopharmaziesegment des Unternehmens umfasst die Therapiebereiche Hämophiliebehandlung, Wachstumshormontherapie und Hormonersatztherapie. Das Unternehmen bietet auch das Produkt Saxenda zur Behandlung von Fettleibigkeit an. Das Unternehmen bietet eine Reihe von Produkten an, darunter NovoLog/NovoRapid, NovoLog Mix/NovoMix, Prandin/NovoNorm, NovoSeven, Norditropin und Vagifem. Zum 31. Dezember 2016 vermarktete das Unternehmen seine Produkte in über 180 Ländern. Die regionale Struktur des Unternehmens besteht aus zwei Geschäftseinheiten: Nordamerika und International Operations.
| Nome | Novo Nordisk 'B' |
| CEO | Lars Fruergaard Jorgensen |
| Sede centrale | Bagsvaerd,
Danimarca |
| Sito web | |
| Settore | Sanità |
| Industria | Prodotti farmaceutici |
| Quotazione in borsa | 07/06/2001 |
| Dipendenti | 59.337 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
XETRA | NOVC.DE |
